Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$4.65 - $7.43 $38,130 - $60,926
-8,200 Reduced 8.12%
92,800 $571,000
Q2 2022

Aug 15, 2022

BUY
$4.82 - $7.7 $348,968 - $557,480
72,400 Added 253.15%
101,000 $535,000
Q1 2022

May 16, 2022

SELL
$6.0 - $16.98 $27,600 - $78,108
-4,600 Reduced 13.86%
28,600 $187,000
Q4 2021

Feb 14, 2022

SELL
$15.19 - $29.33 $776,209 - $1.5 Million
-51,100 Reduced 60.62%
33,200 $544,000
Q3 2021

Nov 15, 2021

SELL
$27.35 - $37.28 $522,385 - $712,048
-19,100 Reduced 18.47%
84,300 $2.45 Million
Q2 2021

Aug 11, 2021

BUY
$26.5 - $38.23 $1.28 Million - $1.85 Million
48,300 Added 87.66%
103,400 $3.59 Million
Q1 2021

May 17, 2021

SELL
$29.83 - $56.81 $1.3 Million - $2.48 Million
-43,600 Reduced 44.17%
55,100 $1.74 Million
Q4 2020

Feb 16, 2021

SELL
$39.12 - $54.99 $457,703 - $643,383
-11,700 Reduced 10.6%
98,700 $4.67 Million
Q3 2020

Nov 16, 2020

BUY
$29.21 - $46.58 $1.66 Million - $2.65 Million
56,900 Added 106.36%
110,400 $5.14 Million
Q2 2020

Aug 14, 2020

BUY
$33.67 - $40.0 $279,461 - $332,000
8,300 Added 18.36%
53,500 $1.93 Million
Q1 2020

May 15, 2020

SELL
$24.28 - $49.8 $619,140 - $1.27 Million
-25,500 Reduced 36.07%
45,200 $1.6 Million
Q4 2019

Feb 14, 2020

BUY
$24.84 - $45.46 $1.15 Million - $2.11 Million
46,400 Added 190.95%
70,700 $3.21 Million
Q3 2019

Nov 14, 2019

SELL
$22.78 - $29.08 $494,326 - $631,036
-21,700 Reduced 47.17%
24,300 $603,000
Q2 2019

Aug 14, 2019

BUY
$15.0 - $22.49 $252,000 - $377,832
16,800 Added 57.53%
46,000 $1.01 Million
Q1 2019

May 15, 2019

BUY
$14.02 - $16.74 $147,210 - $175,769
10,500 Added 56.15%
29,200 $472,000
Q4 2018

Feb 14, 2019

BUY
$10.95 - $15.44 $204,765 - $288,728
18,700 New
18,700 $275,000

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $949M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.